Austrian vaccine developer Hookipa Biotech raises $27.5m series B funding supported by Boehringer Ingelheim Venture Fund and Takeda Ventures, to develop its lead vaccine for immunization against cytomegalovirus and to industrialize its Vaxwave technology for tackling infectious diseases and cancer.
Hookipa Biotech, an Austria-based biotechnology company which is developing new vaccines, has raised €20m ($27.5m) in a series B equity financing led by existing investors, venture capital firmd Sofinnova Partners and Forbion Capital Partners, and joined by three new investors, Boehringer Ingelheim Venture Fund, the corporate venturing affiliate of Germany-based pharmaceutical company Boehringer Ingelheim, Takeda Ventures, the corporate venturing arm of Japan-based Takeda Pharmaceutical Company, and Switzerland-based investment firm BioMedPartners.
This financing brings the total equity finance raised by Hookipa…
